gamma-aminobutyric acid has been researched along with Respiration Disorders in 4 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Respiration Disorders: Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.
| Excerpt | Relevance | Reference |
|---|---|---|
| "At baseline of the clinical trial, the neuropathic pain patients reported significantly more sleep disturbance and daytime somnolence, as well as less quantity and adequacy of sleep than patients in the general US population." | 1.33 | Psychometric properties of the Medical Outcomes Study Sleep measure. ( Hays, RD; Martin, SA; Sesti, AM; Spritzer, KL, 2005) |
| "Episodic airway obstruction and reversible bronchial hyperresponsiveness to non-specific irritants are the major symptoms of asthma." | 1.33 | Bronchial epilepsy or broncho-pulmonary hyper-excitability as a model of asthma pathogenesis. ( Graeme Shaw, D; Hoang, BX; Hoang, C; Levine, SA; Pham, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sullivan, RW | 1 |
| Ryzewski, M | 1 |
| Holland, MG | 1 |
| Marraffa, JM | 1 |
| Hays, RD | 1 |
| Martin, SA | 1 |
| Sesti, AM | 1 |
| Spritzer, KL | 1 |
| Hoang, BX | 1 |
| Levine, SA | 1 |
| Graeme Shaw, D | 1 |
| Pham, P | 1 |
| Hoang, C | 1 |
| Monin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Improving the Quality of Life of People With Multiple Sclerosis and Their Caregivers With a Telemedicine Mindfulness-Based Intervention[NCT02364505] | 156 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Internet-based Cognitive Behavioural Therapy (MoodUP) in Improving Psychological Outcomes Among Perinatal Women: A Prospective Randomised Double-blind Parallel-group Trial[NCT03970057] | 364 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
1 review available for gamma-aminobutyric acid and Respiration Disorders
| Article | Year |
|---|---|
Pharmacology of respiratory control in neonates and children.
Topics: Adenosine; Animals; Apnea; Chemoreceptor Cells; Child; Child, Preschool; Endorphins; gamma-Aminobuty | 1997 |
3 other studies available for gamma-aminobutyric acid and Respiration Disorders
| Article | Year |
|---|---|
Compounded ointment results in severe toxicity in a pediatric patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Body Surface Area; Bradycardia; Clonidine; Combined M | 2013 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Bronchial epilepsy or broncho-pulmonary hyper-excitability as a model of asthma pathogenesis.
Topics: Airway Obstruction; Asthma; Bronchi; Bronchial Hyperreactivity; Cell Membrane; gamma-Aminobutyric Ac | 2006 |